Amgen’s drug targeting ‘undruggable’ protein shines at lung cancer conference

0
7


Amgen presented data for the KRAS G12C inhibitor AMG 510 at the World Conference on Lung Cancer in Barcelona, showing a 54 percent response rate among patients receiving the pivotal study dose.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here